Key facts

Invented name
Lartruvo
Active Substance
Olaratumab
Therapeutic area
Oncology
Decision number
P/0112/2019
PIP number
EMEA-001760-PIP01-15-M03
Pharmaceutical form(s)
Concentrate for solution for infusion
Condition(s) / indication(s)
  • Treatment of osteosarcoma
  • Treatment of soft tissue sarcoma
Route(s) of administration
Intravenous use
Contact for public enquiries

Eli Lilly & Company Limited

E-mail: eu_paediatric@lilly.com 
Tel. +44 (0)1276 483000

Decision type
W: decision granting a waiver in all age groups for all conditions or indications
Decision date

Decision

P/0112/2019: EMA decision of 22 March 2019 on the acceptance of a modification of an agreed paediatric investigation plan and on granting of a waiver in condition for treatment of soft tissue sarcoma for olaratumab (Lartruvo), (EMEA-001760-PIP01-15-M03)

How useful do you find this page?